Stifel Nicolaus analyst Scott Devitt maintained a Buy rating on Netflix (NFLX – Research Report) yesterday and set a price target of $650.00. The company's shares closed last Monday at $627.04, close to its 52-week high of $646.84. According to TipRanks.com, Devitt is a top 100 analyst with an average return of 32.0% and a 67.3% success rate. Devitt covers the Technology sector, focusing on stocks such as Zillow Group Class A, Uber Technologies, and Alphabet Class A. Currently, the analyst consensus on Netflix is a Moderate Buy with an average price target of $633.33, representing a 0.0% upside. In a report issued on September 27, KeyBanc also maintained a Buy rating on the stock with a $645.00 price target. See today’s analyst top recommended stocks >> Based on Netflix's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $7.34 billion and net profit of $1.35 billion. In comparison, last year the company earned revenue of $6.15 billion and had a net profit of $720 million. Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NFLX in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Netflix, Inc. is a subscription-based streaming service through which members can view TV shows, documentaries and movies on any internet-connected device. The company also offers its DVD-by-mail service in the United States. Founded by Marc Randolph and Wilmot Reed Hastings Jr., on August 29, 1997, Netflix is headquartered in Los Gatos, CA. Read More on NFLX: 3 ‘Strong Buy’ Stocks Raymond James Predicts Will Rally Over 60% Square: Lowered Q3 Estimates Don’t Invalidate the Bull Case Keep on Buying Chemocentryx Stock, Says Analyst Following FDA Approval Tilray: A “Rather Flat Print” Keeps This Analyst on the Sidelines General Electric: Targets Are Achievable, but the Stock Is Fully Valued